IP Library Granted Patent US 7,751,982
Granted Patent B2
US 7,751,982 · App. 10/672,429 · Granted Jul 6, 2010

TM leveling methods

Assignee: Elitech Holding B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,751,982
App. No.
10/672,429
Granted
Jul 6, 2010
Kind
B2
Abstract

Methods for designing an oligonucleotide sequence having a selected duplex stability are provided wherein the oligonucleotide portion comprises at least one modified base selected from universal bases, unsubstituted and 3-substituted pyrazolo[3,4-d]pyrimidines and 5-substituted pyrimidines, and optionally having attached minor groove binders and reporter groups.

Claims (34)

1. A method for designing a preferred oligonucleotide sequence having a selected duplex stability comprising:

a) providing an oligonucleotide sequence having N bases and N−1 neighboring base pairs,

b) modifying the oligonucleotide sequence to provide modified oligonucleotide sequences wherein said modified oligonucleotide sequences comprise at least one modified base selected from the group consisting of unsubstituted pyrazolo[3,4-d]pyrimidines, 3-substituted pyrazolo[3,4-d]pyrimidines, and 5-substituted pyrimidines;

c) calculating the duplex stabilities of said modified oligonucleotide sequences using an algorithm applying a nearest-neighbor model for duplex formation thermodynamics for each of the N−1 neighboring base pairs, each nearest neighbor thermodynamic parameter defining a thermodynamic contribution of two corresponding neighboring bases;

d) selecting a preferred oligonucleotide sequence from the modified oligonucleotide sequences having a selected duplex stability; and

e) creating an oligonucleotide comprising the preferred oligonucleotide sequence.

2. A method for designing a preferred oligonucleotide sequence having a selected duplex stability comprising:

a) providing an oligonucleotide sequence having N bases and N−1 neighboring base pairs,

b) modifying the oligonucleotide sequence to provide modified oligonucleotide sequences wherein said modified oligonucleotide sequences comprises comprise at least one modified base selected from the group consisting of unsubstituted pyrazolo[3,4-d]pyrimidines, 3-substituted pyrazolo[3,4-d]pyrimidines, and 5-substituted pyrimidines, and a minor groove binder;

c) calculating a melting temperature (T m ) of said modified oligonucleotide sequences using an algorithm applying nearest neighbor thermodynamic parameters for each of the N−1 neighboring base pairs, each nearest neighbor thermodynamic parameter defining a thermodynamic contribution of two corresponding neighboring bases;

d) selecting a preferred oligonucleotide sequence from the modified oligonucleotide sequences having the selected melting temperature; and

e) creating an oligonucleotide comprising the preferred oligonucleotide sequence.

3. The method of any one of claim 1 or 2 , wherein said oligonucleotide sequence is derived from a database source.

4. The method of claim 3 , wherein said database source is GENBANK.

5. The method of any one of claim 1 or 2 , wherein said at least one modified base is a member selected from the group consisting of a base attached to an amino acid, a polyamide nucleic acid (PNA), and a locked nucleic acid sugar.

6. The method of claim 5 , wherein said modified base is attached to PNA.

7. The method of claim 5 , wherein said modified base is attached to a locked nucleic acid sugar.

8. The method of any one of claim 1 or 2 , wherein said oligonucleotide has an enhanced ability of mismatch discrimination, in comparison to unmodified nucleotides.

9. The method of any one of claims 1 or 2 , wherein said at least one modified base is a member selected from the group consisting of PPA, PPG, PPPA, PPPG, PU, PC, HOPU, HOBuU, HOBuC, (NH 2 ) 2 PPPA, (NH 2 ) 2 PPPAOH, (NH 2 ) 2 BuPPAOH, (NH 2 ) 2 PPAI, and HOBuPPG.

10. The method of claim 1 , wherein said oligonucleotide has attached to it one or more members selected from the group consisting of a minor groove binder, a fluorophore, and a quencher.

11. The method of claim 10 , wherein said oligonucleotide has a minor groove binder attached thereto.

12. The method of claim 2 or 11 , wherein said minor groove binder has a formula selected from the group consisting of:

wherein

the subscript m is an integer of from 2 to 5;

the subscript r is an integer of from 2 to 10; and

each R a and R b is independently a linking group to said modified oligonucleotide, H, OR c , NR c R d , COOR c , or —CONR c R d wherein each R c and R d is selected from the group consisting of H, (C 1 -C 12 )heteroalkyl, (C 2 -C 12 )heteroalkenyl, (C 2 -C 12 )heteroalkynyl, (C 1 -C 12 )alkyl, (C 2 -C 12 )alkenyl, (C 2 -C 12 )alkynyl, aryl(C 1 -C 12 )alkyl, and aryl.

13. The method of claim 11 , wherein said minor groove binder is attached to the oligonucleotide via a quencher molecule.

14. The method of any one of claim 1 or 2 , wherein said algorithm predicts the melting temperature (T m ) of said oligonucleotide with an accuracy of about +/−2° C.

15. The method of any one of claim 1 or 2 , wherein said method is applied to establish appropriate conditions for hybridization, renaturation, mapping variations of base compositions of sequences, or determination of sequence complexity and divergence.

16. The method of any one of claim 1 or 2 , wherein said oligonucleotide is a capture probe in an array.

17. The method of claim 6 , wherein said oligonucleotide has an enhanced ability of mismatch discrimination, in comparison to unmodified nucleotides.

18. The method of claim 7 , wherein said oligonucleotide has an enhanced ability of mismatch discrimination, in comparison to unmodified nucleotides.

19. The method of claim 1 , wherein the oligonucleotide sequence comprises a universal base and wherein the modified oligonucleotide sequences comprise the universal base and at least one modified base selected from the group consisting of unsubstituted pyrazolo[3,4-d]pyrimidines, 3-substituted pyrazolo[3,4-d]pyrimidines, and 5-substituted pyrimidines.

20. The method of claim 2 , wherein the oligonucleotide sequence comprises a universal base and wherein the modified oligonucleotide sequences comprise the universal base and at least one modified base selected from the group consisting of unsubstituted pyrazolo[3,4-d]pyrimidines, 3-substituted pyrazolo[3,4-d]pyrimidines, and 5-substituted pyrimidines.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: ELITECHGROUP B.V.
To: ELITECHGROUP, INC.
Reel/Frame 048078/0553 →
CHANGE OF NAME Recorded Mar 10, 2017
From: ELITECH HOLDING BV
To: ELITECHGROUP B.V.
Reel/Frame 041974/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2009
From: NANOGEN, INC.; EPOCH BIOSCIENCES, INC.; NANOTRONICS, INC.
To: ELITECH HOLDING B.V.
Reel/Frame 023260/0182 →
SECURITY AGREEMENT Recorded Jun 20, 2008
From: EPOCH BIOSCIENCES, INC.
To: DRUG ROYALTY LP1
Reel/Frame 021127/0646 →
SECURITY AGREEMENT Recorded Mar 28, 2008
From: EPOCH BIOSCIENCES, INC.
To: DRUG ROYALTY LP2
Reel/Frame 020710/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2006
From: EPOCH BIOSCIENCES, INC.
To: DRUG ROYALTY TRUST 9
Reel/Frame 018362/0870 →
Continuity (9)
Continuation 1003230700 · Dec 21, 2001
Continuation 0979698800 · Feb 28, 2001
Continuation In Part 0972495900 · Nov 28, 2000
Continuation In Part 0964095300 · Aug 16, 2000
Division 0905483200 · Apr 3, 1998
Continuation In Part 0943138500 · Nov 1, 1999
Continuation 0905483000 · Apr 3, 1998
Provisional Application 6018604600 · Mar 1, 2000
Related Publication 20050075491A1 · Apr 7, 2005